# A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus

> **NCT06530849** · PHASE1,PHASE2 · RECRUITING · sponsor: **Gracell Biotechnologies (Shanghai) Co., Ltd.** · enrollment: 118 (estimated)

## Conditions studied

- Refractory Systemic Lupus Erythematosus

## Interventions

- **DRUG:** GC012F Injection

## Key facts

- **NCT ID:** NCT06530849
- **Lead sponsor:** Gracell Biotechnologies (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-22
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06530849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06530849, "A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT06530849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*